左甲状腺素替代治疗的过度使用:一种及时的诊断方法
这项前瞻性队列随访研究纳入291例缺乏明确甲状腺功能减退诊断而长期服用左甲状腺素(LT4)的患者,暂停治疗6-8周后评估甲状腺功能。结果显示60.8%的患者停药后甲状腺功能正常,提示LT4过度使用普遍;超声弥漫性不均匀回声是预测潜在甲减的独立因素。研究建议对诊断不明确者采用停药6-8周并前后检测TSH的策略。
要点
- 缺乏明确甲减诊断而长期服用LT4的患者中,60.8%停药后甲状腺功能正常,提示过度治疗普遍。
- 超声弥漫性不均匀回声与停药后出现甲减显著相关(p<0.001),可能有助于识别真正需要治疗者。
- 对诊断不明确者,可考虑停药6-8周并在前后检测TSH,作为一线评估策略。
核心结论
- 缺乏明确甲减诊断而长期服用LT4的患者中过度使用普遍,60.8%停药后甲状腺功能正常(p<0.001)。
- 超声弥漫性不均匀回声在停药后出现甲减的患者中显著更常见(p<0.001)。
研究设计与样本
- 前瞻性临床队列随访研究,纳入291例(84%女性)年龄48±16岁、正在LT4替代治疗但缺乏明确甲减诊断的受试者。
- 暂停LT4治疗,在基线和停药6-8周后检测TSH和游离甲状腺素,并行甲状腺超声。
- TSH≥4.5 IU/mL定义为潜在甲减。
主要发现
- 291例中114例停药后出现甲减(A组),177例维持甲状腺功能正常(B组),分别为39.2%与60.8%(p<0.001)。
- 两组在性别、家族史、年龄、体重指数、治疗时长、基线TSH和游离甲状腺素、甲状腺体积及甲状腺自身抗体存在方面具有可比性。
- 超声弥漫性不均匀回声在A组显著更高(p<0.001)。
关键数值与推荐
- TSH≥4.5 IU/mL视为潜在甲减。
- 建议在开始LT4治疗前明确诊断,并对长期LT4治疗者定期评估继续治疗的必要性。
- 对诊断未明确者,可考虑停药6-8周并在前后检测TSH作为一线评估策略。
临床怎么用
- 对缺乏明确甲减诊断而长期服用LT4的患者,应重新评估诊断并考虑停药试验。
- 可采用停药6-8周并在前后检测TSH的策略,以识别真正需要替代治疗的患者。
- 甲状腺超声显示弥漫性不均匀回声可能提示停药后出现甲减的风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Levothyroxine (LT4) is one of the most prescribed drugs worldwide. Once started, approximately 90% of patients continue treatment long term. However, accumulating evidence suggests that many patients, for whom the indication for its administration is not adequately established and the diagnosis is not well documented, are overusing it. This study aimed to evaluate the necessity for and determine potential prognostic factors of long-term LT4 supplementation. METHODS: A prospective clinical cohort follow-up study was carried out. In 291 subjects (84% females) aged 48 ± 16 years on LT4 replacement therapy without a solid diagnosis of hypothyroidism being provided, the treatment was paused. At the beginning and after six to eight weeks of treatment discontinuation, thyrotropin (TSH) and free thyroxine levels were assessed, and thyroid ultrasound was performed. A TSH value of ≥4.5 IU/mL was considered as underlying hypothyroidism. RESULTS: Among the 291 individuals, 114 became hypothyroid (group A), while 177 subjects remained euthyroid off LT4 (group B; 39.2% vs. 60.8%, p < 0.001). The groups were comparable regarding sex, family history, age, body mass index, duration of treatment, basal TSH and free thyroxine values, thyroid volume, and presence of thyroid autoantibodies. However, diffuse inhomogeneous echogenicity on ultrasound examination was significantly higher (p < 0.001) in group A. CONCLUSIONS: These findings suggest considerable overuse of thyroxine therapy. The results underline the initial need to establish the diagnosis firmly before treatment initiation and to undertake periodic evaluation of all patients on chronic LT4 treatment as to the necessity for treatment continuation. In all patients on long-term LT4 therapy in whom the diagnosis has not been definitively established, it appears rational to introduce a six- to eight-week period of LT4 replacement therapy discontinuation, preceded and followed by TSH tests, as the first-line approach-a procedure that could be implemented as part of a common strategy among the scientific community to decrease current LT4 overuse.
引用
- Livadas S, Bothou C, Androulakis I, et al. Levothyroxine Replacement Therapy and Overuse: A Timely Diagnostic Approach. Thyroid. 2018. PMID: 30351232. doi:10.1089/thy.2018.0014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。